AbbVie Shares Outstanding 2010-2018 | ABBV

AbbVie shares outstanding history from 2010 to 2018. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
  • AbbVie shares outstanding for the quarter ending December 31, 2018 were 1.546B, a 3.56% decline year-over-year.
  • AbbVie 2018 shares outstanding were 1.546B, a 3.56% decline from 2017.
  • AbbVie 2017 shares outstanding were 1.603B, a 1.72% decline from 2016.
  • AbbVie 2016 shares outstanding were 1.631B, a 0.37% decline from 2015.
AbbVie Annual Shares Outstanding
(Millions of Shares)
2018 1,546
2017 1,603
2016 1,631
2015 1,637
2014 1,610
2013 1,604
2012 1,577
2011 1,577
2010 1,577
2009 0
AbbVie Quarterly Shares Outstanding
(Millions of Shares)
Q4 2018 1,546
Q3 2018 1,515
Q2 2018 1,572
Q1 2018 1,596
Q4 2017 1,603
Q3 2017 1,603
Q2 2017 1,600
Q1 2017 1,603
Q4 2016 1,631
Q3 2016 1,640
Q2 2016 1,632
Q1 2016 1,625
Q4 2015 1,637
Q3 2015 1,664
Q2 2015 1,633
Q1 2015 1,608
Q4 2014 1,610
Q3 2014 1,610
Q2 2014 1,608
Q1 2014 1,609
Q4 2013 1,604
Q3 2013 1,605
Q2 2013 1,609
Q1 2013 1,605
Q4 2012 1,577
Q3 2012 1,577
Q2 2012 1,577
Q1 2012 1,577
Q4 2011 1,585
Q3 2011 1,300
Q2 2011 1,571
Q1 2011 0
Q4 2010 0
Q4 2009 0
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $115.027B $32.753B
AbbVie is a global, research-based biopharmaceutical company. AbbVie combines the focus and passion of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. AbbVie aims to help patients' live healthier lives and collaborate on sustainable healthcare solutions.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $371.636B 16.85
Pfizer (PFE) United States $237.400B 13.29
Merck (MRK) United States $199.302B 17.03
Novartis AG (NVS) Switzerland $178.563B 15.19
Eli Lilly (LLY) United States $120.673B 20.95
Novo Nordisk (NVO) Denmark $118.536B 19.17
Sanofi (SNY) France $103.057B 12.72
GlaxoSmithKline (GSK) United Kingdom $99.174B 13.02
AstraZeneca (AZN) United Kingdom $98.200B 11.20
Bristol-Myers Squibb (BMY) United States $74.835B 11.51